863 related articles for article (PubMed ID: 12036919)
41. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines.
Yamanaka T; Shiraki K; Sugimoto K; Ito T; Fujikawa K; Ito M; Takase K; Moriyama M; Nakano T; Suzuki A
Hepatology; 2000 Sep; 32(3):482-90. PubMed ID: 10960439
[TBL] [Abstract][Full Text] [Related]
42. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
43. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
44. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
45. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Hopkins-Donaldson S; Bodmer JL; Bourloud KB; Brognara CB; Tschopp J; Gross N
Cancer Res; 2000 Aug; 60(16):4315-9. PubMed ID: 10969767
[TBL] [Abstract][Full Text] [Related]
46. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.
Griffith TS; Chin WA; Jackson GC; Lynch DH; Kubin MZ
J Immunol; 1998 Sep; 161(6):2833-40. PubMed ID: 9743343
[TBL] [Abstract][Full Text] [Related]
47. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
48. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
Azuhata T; Scott D; Griffith TS; Miller M; Sandler AD
J Pediatr Surg; 2006 Aug; 41(8):1431-40. PubMed ID: 16863850
[TBL] [Abstract][Full Text] [Related]
49. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
[TBL] [Abstract][Full Text] [Related]
50. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
51. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Nesterov A; Nikrad M; Johnson T; Kraft AS
Cancer Res; 2004 Jun; 64(11):3922-7. PubMed ID: 15173003
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
53. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
[TBL] [Abstract][Full Text] [Related]
54. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
55. Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone.
Huang L; Xu J; Li K; Zheng MH; Kumta SM
Bone; 2004 Jun; 34(6):971-81. PubMed ID: 15193543
[TBL] [Abstract][Full Text] [Related]
56. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Yoo J; Lee YJ
Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
[TBL] [Abstract][Full Text] [Related]
57. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
58. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
[TBL] [Abstract][Full Text] [Related]
59. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
[TBL] [Abstract][Full Text] [Related]
60. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]